PLoS ONE (Jan 2012)

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.

  • William K Decker,
  • Nina Shah,
  • Dongxia Xing,
  • Ruth Lapushin,
  • Sufang Li,
  • Simon N Robinson,
  • Hong Yang,
  • Simrit Parmar,
  • Matthew M Halpert,
  • Michael J Keating,
  • John G Gribben,
  • Jeffrey J Molldrem,
  • Elizabeth J Shpall,
  • William G Wierda

DOI
https://doi.org/10.1371/journal.pone.0051390
Journal volume & issue
Vol. 7, no. 12
p. e51390

Abstract

Read online

Though remissions have been observed following allo-HSCT for the treatment of CLL, many CLL patients are ineligible for transplant due to the lack of HLA-compatible donors. The use of umbilical cord blood (UCB) permits transplantation of many patients who lack HLA-compatible donors due to reduced requirements for stringent HLA matching between graft and recipient; however, disease relapse remains a concern with this modality. The generation of CLL-specific CTL from UCB T-cells, primed and expanded against the leukemic clone, might enhance the GVL effect and improve outcomes with UCB transplantation. Here we report the generation of functional, CLL-specific CTL using CD40-ligated CLL cells to prime partially-HLA matched UCB T-cells. Functionality and specificity were demonstrated by immune synapse assay, IFN-γ ELISpot, multi-parametric intracellular cytokine flow cytometry, and (51)Cr release assay. The use of patient-specific, non-CLL controls demonstrated the generation of both alloantigen and CLL-specific responses. Subsequently, we developed a clinically-applicable procedure permitting separation of alloreactive CTL from leukemia-specific CTL. Leukemia-specific CTL were able to mediate in vivo killing of CLL in humanized mice without concurrent or subsequent development of xenoGVHD. Our results demonstrate that generation of CLL-specific effectors from UCB is feasible and practical, and the results support further exploration of this strategy as a treatment modality for CLL.